Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2

ValuationView details →

P/E (Fwd)

35.4x

EV/EBITDA

18.3x

Market Cap

$10.20B

MomentumView details →

1D Return

+4.46%

YTD Return

+17.50%

RSI (14)

97.2

ValuationView details →

P/E (Fwd)

35.4x

EV/EBITDA

18.3x

Market Cap

$10.20B

RSI (14)

97.2

MomentumView details →

1D Return

+4.46%

YTD Return

+17.50%

ProfitabilityView details →

Gross Margin

51.90%

Net Margin

8.59%

EBITDA Margin

20.65%

ROE (TTM)

3.10%

ROA (TTM)

2.17%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+1.37%

EPS YoY

−29.17%

FCF YoY

+1.61%

Revenue CAGR 3Y

−2.68%

EPS CAGR 3Y

+142.64%

EBITDA YoY

−22.09%

EarningsView details →

EPS (Actual)

$2.62

EPS Surprise

47.19%

Beats (12Q)

7/12

Next Q EPS Est

$2.19

Avg Surprise (4Q)

374.70%

Rev Surprise

4.19%

Capital & dividendView details →

Debt/Equity

0.17x

Current Ratio

3.14x

Quick Ratio

2.33x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.59B

Net Income (TTM)

222.40M

Op. CF (TTM)

492.60M

Next earningsOct 22, 2026 →

Latest newsMore news →

First Trust Advisors LP reduced its stake in Bio-Rad Laboratories, Inc. by 97.3% during the quarter, selling 55,710 shares and retaining 1,522 shares, according to a recent SEC filing.23d ago

Bio-Rad Laboratories reported its financial results for the second quarter ended June 30, 2026, with reported revenue flat year-over-year, as growth in Clinical Diagnostics was offset by softness in Life Science.31d ago

Similar companies

Insulet CorporationPODD Bio-Rad Laboratories, Inc.BIO Glaukos CorporationGKOS Globus Medical, Inc.GMED Shenzhen Edge Medical Co Ltd02675.HK 心脉医疗688016.SH Find similar companies →

Latest newsMore news →

First Trust Advisors LP reduced its stake in Bio-Rad Laboratories, Inc. by 97.3% during the quarter, selling 55,710 shares and retaining 1,522 shares, according to a recent SEC filing.23d ago Bio-Rad Laboratories reported its financial results for the second quarter ended June 30, 2026, with reported revenue flat year-over-year, as growth in Clinical Diagnostics was offset by softness in Life Science.31d ago